ArticleClinical cardiology2018

Design of the randomized, placebo-controlled evolocumab for early reduction of LDL-cholesterol levels in patients with acute coronary syndromes (EVOPACS) trial.

Konstantinos C Koskinas et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.